Psychopharmacology and Psychiatry Updates SSRIs and Anticoagulants: Navigating Bleeding Risk
Mar 12, 2025
Scott Beach, M.D., a leading expert in pharmacology, dives into a significant 23-year study examining the interplay between SSRIs and oral anticoagulants. He discusses the startling 33% increased risk of major bleeding events observed in patients with atrial fibrillation using both treatments. The conversation also highlights critical strategies for safe prescribing and monitoring, particularly during the initial treatment phase. Beach emphasizes the need for personalized approaches to mitigate risks, including potential medication adjustments and diligent oversight.
AI Snips
Chapters
Transcript
Episode notes
Increased Bleeding Risk with Combination
- Combining SSRIs with oral anticoagulants increases major bleeding risk by 33%, especially in the first month.
- This risk declines significantly after six months, regardless of SSRI potency or patient demographics.
SSRI Potency and Drug Interactions
- Bleeding risk does not vary with SSRI potency; paroxetine and escitalopram carry similar risks.
- Cytochrome P450 drug interactions contribute minimally to increased bleeding risk with SSRIs and anticoagulants.
Manage Bleeding Risk Strategically
- Monitor patients closely during the first 30 days of combined SSRI and anticoagulant therapy to catch bleeding early.
- Collaborate with PCPs or cardiologists to consider switching warfarin to DOACs and possibly add proton pump inhibitors to reduce bleeding risk.